Athenex Inc. and SunGen Pharma enter into U.S. joint venture agreement for a portfolio of 7 approved pharmaceutical products

Buffalo, NY and Hong Kong – Athenex Pharmaceutical Division and SunGen Pharma LLC, DBA Peterson Pharmaceuticals, a specialty pharmaceutical company located in New Jersey, today announced a joint venture agreement to launch and market 7 pharmaceutical products, both injectable and solid oral dosage, in the United States. Many of these products are therapeutically relevant to…

Dr. Daniel Von Hoff, MD, F.A.C.P. Joins Athenex’s Clinical Scientific Advisory Board

Buffalo, NY and Hong Kong – Athenex Inc., an innovative oncology pharmaceutical company with a broad range of proprietary oncology pharmaceutical products and product candidates under development, is pleased to welcome Dr. Daniel Von Hoff, MD, F.A.C.P. to its Clinical Scientific Advisory Board (SAB). Dr. Von Hoff is highly regarded as a medical oncologist and…

Athenex, Inc. and Gland Pharma enter into U.S. supply and marketing collaboration for a portfolio of more than 20 specialty injectable pharmaceutical products

Buffalo, NY and Hong Kong – Athenex Pharmaceutical Division and Gland Pharma, one of the major injectable pharmaceutical companies in India, announced today a partnership agreement to launch and market injectable products in the United States.  Many of these products are therapeutically relevant to the Athenex proprietary pipeline of products under development.  In addition, the…

Athenex Announces the Addition of James Hussey to Lead its Commercial Business Activities

Buffalo, NY and Hong Kong – Athenex, Inc. announced today that James Hussey has joined the Company as Executive Vice President of Athenex Pharmaceutical Division. In this capacity, Mr. Hussey will be responsible for the execution of the commercial aspects of this business unit including strategy, new products, manufacturing, distribution, sales and marketing. Mr. Hussey…

Athenex Announces Jeffrey Yordon to Lead Newly Formed Specialty Products Division

Buffalo, NY and Hong Kong– Athenex, Inc. announced today that Jeffrey Yordon has joined the Company as President of the newly formed subsidiary, Athenex Specialty Products. In this capacity, Mr. Yordon will be responsible for all aspects of the business unit including strategy, new products, manufacturing, distribution, sales and marketing.   Prior to joining Athenex,…

Athenex Announces the Addition of David Cutler, MD, FRCP(C) to its Global Clinical Development Team

Buffalo, NY and Hong Kong – Athenex, Inc. announced today that David Cutler, MD, FRCP(C), has joined Athenex as Vice President of Clinical Development working together with Dr. Rudolf Kwan, Chief Medical Officer. Dr. Cutler has extensive expertise in oncology drug development including a recent leadership position as Distinguished Clinical Scientist, Translational Pharmacology in Merck,…

Antony Leung, Group CEO of Nan Fung Group and former Financial Secretary of Hong Kong Special Administrative Region, to join the Athenex Board of Directors

BUFFALO, N.Y., and HONG KONG — Athenex, Inc announced today that Mr. Antony Leung has accepted the invitation to join the Athenex Board of Directors. Antony Leung, Hon.LLD, GBS, JP, former Financial Secretary of Hong Kong Special Administrative Region, is currently Group CEO of Nan Fung Group, a leading regional conglomerate focusing on property & investment businesses. He is…

Governor Cuomo Announces Major Expansion of Athenex — Creating 1,400 Jobs in Western New York

Athenex (formerly Kinex) to invest $1.62 billion in drug discovery and advanced manufacturing partnership, creating 900 jobs in Dunkirk and 500 jobs in Buffalo over the next ten years. State investing $225 million to support the Buffalo Medical Innovation and Commercialization Hub and help create new opportunities for the region.   Governor Andrew M. Cuomo…

Athenex Announces the Addition of Simon Pedder, PhD and Raymond Yeung, MSc, MBA to its Global Leadership Team

Buffalo, NY and Hong Kong – Athenex, Inc. announced today that Simon Pedder, PhD, has joined Athenex as Vice President of Corporate Strategy and Business Development based in the U.S. and Mr. Raymond Yeung, MSc, MBA has joined as Senior Director and Deputy Head of Clinical Research and Regulatory Affairs, Asia-Pacific, based in Hong Kong.   Dr. Pedder…

Athenex Announces US FDA Allowance of the Investigational New Drug Application of Oradoxel, the Proprietary Oral Form of Docetaxel

Buffalo, NY and Hong Kong- Athenex, Inc. announced today that it has received United States Food and Drug Administration (US FDA) allowance to proceed in the clinic with its proprietary oral form of Docetaxel. This allowance to proceed represents Athenex’s sixth successful oncology investigational new drug (IND) application by the US FDA (5 oral anticancer…